Prof. Dr. Ulrike Haug

Education and academic positions
  • Since 2015 Professor of Clinical Epidemiology and Pharmacoepidemiology at the University of Bremen and Head of the Department Clinical Epidemiology at the Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
  • 2010-2015 Group Leader, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 03/2013 Habilitation and Venia Legendi for Epidemiology at the Medical Faculty of the Ruprecht-Karls-University of Heidelberg
  • 2008-2009 Visiting Assistant Research Professor, Division of Health Policy and Management, School of Public Health, University of Minnesota, Minneapolis, USA
  • 2006-2010 Postdoctoral Research Fellow, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • 07/2006 PhD in Epidemiology, University of Heidelberg
  • 2002-2005 PhD program in Epidemiology (DFG-funded Graduiertenkolleg 793), German Centre for Research on Ageing, Heidelberg, Germany
  • 01/2003 Approbation as Pharmacist
  • 2001-2002 Working in a pharmacy (Heidelberg) and pharmaceutical industry (Karlsruhe) for accreditation as Pharmacist
  • 1997-2001 Study of Pharmacy at the University of Wurzburg, Germany
Professional activities
  • Since 2020 Selected as a CORE member of the ISPE RWE Task Force: RWE and Oncology Subgroup
  • Since 2019 Elected member of the Scientific Council of the International Agency for Research on Cancer (IARC)
  • Since 2019 Invited member of the expert committee “Cancer Prevention” of the National Decade Against Cancer
  • Since 2018 Head of expert group “Medication and Pharmacoepidemiology” of the German National Cohort (NAKO)
  • Since 2018 Section editor “Pharmacoepidemiology” of the journal Current Epidemiology Reports
  • Since 2018 Invited member and deputy chair of the advisory board of the German Centre for Cancer Registry Data (ZFKD) at the Robert Koch Institute
  • Since 2017 Invited member of the expert advisory board of the foundation “Stiftung LebensBlicke”
  • Since 2016 Invited member of the expert committee “Early cancer detection” of the German Cancer Aid
  • Since 2016 Member of the data and safety monitoring board of the European Polyp Surveillance (EPOS) trials
  • Since 2016 Mentor in mentoring programs of the University of Düsseldorf and the University of Würzburg
  • 2015 Consultant to the Ministry of Health of the Grand Duchy of Luxembourg on the establishment of an organized colon cancer screening program
  • Since 2015 Invited member of the international expert working group “Right-sided lesions and interval colorectal cancer” (World Endoscopy Organization)
  • Since 2012 Invited member of the international expert working group “Development and evaluation of new tests for colorectal cancer screening” (World Endoscopy Organization)
  • Since 2012 Reviewer for national and international funding organizations (e.g. German Research Foundation, The Netherlands Organization for Health Research and Development)


  • Epidemiology of colorectal carcinoma, colorectal cancer screening, cancer prevention in risk groups, pharmacoepidemiology

    Selected BIPS-Publications

  • Articles with peer-review

  • Heinig M, Schwarz S, Haug U. Self-selection for mammography screening according to use of hormone replacement therapy: A systematic literature review. Cancer Epidemiology. 2021;71(Part A):101812.
  • Schäfer W, Reinders T, Riedel O, Haug U. How often are antidepressants prescribed off-label among older adults in Germany? A claims data analysis. British Journal of Clinical Pharmacology. 2021;87(4):1778-1789.
  • Beyerle J, Holowatyj AN, Haffa M, Frei E, Gigic B, Schrotz-King P, Böhm J, Habermann N, Stiborova M, Scherer D, Koelsch T, Skender S, Becker N, Herpel E, Schneider M, Ulrich A, Schirmacher P, Chang-Claude J, Brenner H, Hoffmeister M, Haug U, Owen RW, Ulrich CM. Expression patterns of xenobiotic-metabolizing enzymes in tumor and adjacent normal mucosa tissues among patients with colorectal cancer: The ColoCare Study. Cancer Epidemiology, Biomarkers & Prevention. 2020;29(2):460-469.
  • Haug U, Coupé VMH. The cumulative false-positive rate in colorectal cancer screening: A Markov analysis. European Journal of Gastroenterology and Hepatology. 2020;32(5):575-580.
  • Langner I, Riedel O, Czwikla J, Heinze F, Rothgang H, Zeeb H, Haug U. Linkage of routine data to other data sources in Germany: A practical example illustrating challenges and solutions. Das Gesundheitswesen. 2020;82(Suppl. 2):S117-S121.
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Individual antidepressants and the risk of fractures in older adults: A new user active comparator study. Clinical Epidemiology. 2020;12:667-678.
  • Schink T, Wentzell N, Dathe K, Onken M, Haug U. Estimating the beginning of pregnancy in German claims data: Development of an algorithm with a focus on the expected delivery date. Frontiers in Public Health. 2020;8:350.
  • Scholle O, Kollhorst B, Haug U. Are prescribers not aware of cardiovascular contraindications for diclofenac? A claims data analysis. Journal of Internal Medicine. 2020;287(2):171-179.
  • Buskermolen M, Cenin DR, Helsingen LM, Guyatt G, Vandvik PO, Haug U, Bretthauer M, Lansdorp-Vogelaar I. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: A microsimulation modelling study. The BMJ. 2019;367:l5383.
  • Langner I, Haug U, Scholle O, Lindemann C, Schröder C, Riedel O. Potential explanations for increasing methylphenidate use in children and adolescents with attention-deficit/hyperactivity disorder in Germany from 2004 to 2013. Journal of Clinical Psychopharmacology. 2019;39(1):39-45.
  • Langner I, Ohlmeier C, Haug U, Hense H-W, Czwikla J, Zeeb H. Implementation of an algorithm for the identification of breast cancer deaths in German health insurance claims data: A validation study based on a record linkage with administrative mortality data. BMJ Open. 2019;9:e026834.
  • Langner I, Ohlmeier C, Zeeb H, Haug U, Riedel O. Individual mortality information in the German Pharmacoepidemiological Research Database (GePaRD): A validation study using a record linkage with a large cancer registry. BMJ Open. 2019;9:e028223.
  • Oppelt KA, Luttmann S, Kraywinkel K, Haug U. Incidence of advanced colorectal cancer in Germany: Comparing claims data and cancer registry data. BMC Medical Research Methodology. 2019;19:142.
  • Overbeek J, Kuiper J, van der Heijden A, Labots M, Haug U, Herings R, Nijpels G. Sex- and site-specific differences in colorectal cancer risk among people with type 2 diabetes. International Journal of Colorectal Disease. 2019;34(2):269-276.
  • Pisa F, Reinold J, Kollhorst B, Haug U, Schink T. Antidepressants and the risk of traumatic brain injury in the elderly: Differences between individual agents. Clinical Epidemiology. 2019;11:185-196.
  • Bauer A, Riemann JF, Seufferlein T, Reinshagen M, Hollerbach S, Haug U, Unverzagt S, Boese S, Ritter-Herschbach M, Jahn P, Frese T, Harris M, Landenberger M. Invitation to screening colonoscopy in the population at familial risk for colorectal cancer: A cluster-randomized study aimed at increasing participation rates. Deutsches Ärzteblatt International. 2018;115(43):715-722.
  • Czwikla J, Giersiepen K, Langner I, Enders D, Heinze F, Rothgang H, Haug U, Zeeb H, Hense H-W. A cohort study of mammography screening finds that comorbidity measures are insufficient for controlling selection bias. Journal of Clinical Epidemiology. 2018;104:1-7.
  • Haug U. Aktueller Stand der Evidenz und Entwicklung der Darmkrebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1513-1516.
  • Haug U, Langner I, Zeeb H. Evaluation von organisierten Programmen zur Krebsfrüherkennung: Allgemeine Aspekte und aktueller Stand in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1500-1504.
  • Haug U, Riedel O, Cholmakow-Bodechtel C, Olsson L. First-degree relatives of cancer patients: A target group for primary prevention? A cross-sectional study. British Journal of Cancer. 2018;118(9):1255-1261.
  • Oppelt KA, Haug U. Schmerztherapie bei Darmkrebspatienten - Längsschnittanalysen auf Versichertendaten basierend. Der Onkologe. 2018;24(11):848-860.
  • Plath J, Siebenhofer A, Haug U, Koné I, Hechtner M, Blumenstein I, Schulz-Rothe S, Gerlach FM, Guethlin C. Utilization of colonoscopy and colonoscopic findings among individuals aged 40-54 years with a positive family history of colorectal cancer: A cross-sectional study in general practice. European Journal of Cancer Prevention. 2018;27(6):539-545.
  • Rutter MD, Beintaris I, Valori R, Chiu HM, Corley D, Dekker E, Forsberg A, Freixas MC, Gore-Booth J, Haug U, Kaminski MF, Matsuda T, Meijer GA, Morris E, Plumb A, Rabeneck L, Robertson D, Schoen R, Singh H, Tinmouth J, Young G, Sanduleanu S. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. Gastroenterology. 2018;155(3):909-925.e3.
  • Wentzell N, Haug U, Schink T, Engel S, Liebentraut J, Linder R, Onken M, Schaefer C, Dathe K. Valproatverordnungen bei Mädchen und Frauen im gebärfähigen Alter in Deutschland: Untersuchung zeitlicher Trends basierend auf Versichertendaten. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(8):1022-1029.
  • Wentzell N, Schink T, Haug U, Ulrich S, Niemeyer M, Mikolajczyk R. Optimizing an algorithm for the identification and classification of pregnancy outcomes in German claims data. Pharmacoepidemiology and Drug Safety. 2018;27(9):1005-1010.
  • Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: Can the screening interval be extended? Gut. 2017;66(7):1262-1267.
  • Zia Shams A, Haug U. Strategies for prevention of gastrointestinal cancers in developing countries: A systematic review. Journal of Global Health. 2017;7(2):020405.
  • Fiederling J, Zia Shams A, Haug U. Validity of self-reported family history of cancer: A systematic literature review on selected cancers. International Journal of Cancer. 2016;139(7):1449-1460.
  • Haug U, Becker N. Immunologische Stuhlbluttests zur Darmkrebsfrüherkennung: Schnelltests sind keine vertretbare Option für ein qualitätsgesichertes Programm. Deutsche Medizinische Wochenschrift. 2016;141(10):729-731.
  • Young GP, Senore C, Mandel JS, Allison JE, Atkin WS, Benamouzig R, Bossuyt P, De Silva M, Guittet L, Halloran SP, Haug U, Hoff G, Itzkowitz SH, Leja M, Levin B, Meijer GA, O'Morain CA, Parry S, Rabeneck L, Rozen P, Saito H, Schoen RE, Seaman HE, Steele RJC, Sung JJY, Winawer SJ. Recommendations for a step-wise comparative approach to the evaluation of new screening tests for colorectal cancer. Cancer. 2016;122(6):826-839.
  • Editorials

  • Haug U, Pigeot I. Krebsfrüherkennung: Ja oder Nein? Facetten einer komplexen Antwort. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz. 2018;61(12):1481-1483.
  • Haug U. Flexible sigmoidoscopy screening for colorectal cancer. The BMJ. 2017;356:j75.
  • Position Papers

  • Deutsche Gesellschaft für Epidemiologie (DGEpi), in collaboration with Haug U, Hense H-W, Twardella D. Stellungnahme zum Beschlussentwurf des G-BA: Richtlinie für organisierte Krebsfrüherkennungsprogramme und Änderung der Krebsfrüherkennungs-Richtlinie. 2018.
  • Editorships

  • Pigeot I, Haug U. Stand der Krebsfrüherkennung in Deutschland. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 61(12). Springer. 2018.
  • Contributions to books and proceedings

  • Haug U. Screening des kolorektalen Karzinoms. In: Schmoll H-J, editors. Kompendium internistische Onkologie. 5. Auflage. Berlin, Heidelberg: Springer. 2020.
  • Commentaries

  • Haug U, Senore C, Corley D. Promises and potential pitfalls of shared decision-making in cancer screening. Gastroenterology. 2020;158(4):802-805.
  • Senore C, Haug U. Faecal immunochemical tests have the potential for correctly ruling out colorectal cancer in symptomatic patients. BMJ Evidence-Based Medicine. 2018;23(3):113-114.

For further publications please follow this link:

  • Vision Zero Präventionsaward 2020
    Netzwerk gegen Krebs (2020)
    Besondere Verdienste zum Thema Prävention und Früherkennung von Darmkrebs
  • Mitglied von / Member of
    AcademiaNet – Expert Database of Outstanding Women in Science (2017)
  • Darmkrebs-Präventionspreis 2016 / Colorectal Cancer Prevention Award 2016
    Deutsche Krebsgesellschaft, Stiftung LebensBlicke und Deutsche Krebsstiftung (2016)
    Darmkrebsvorsorge und -früherkennung
  • Reisestipendium (travel grant) “Best submitted abstracts” / Oral Free Paper Prize
    United European Gastroenterology Week (2014)
  • Felix-Burda-Award for Medical Prevention
    Felix Burda Stiftung (2009)
    Förderung der Darmkrebsprävention und -früherkennung in Deutschland
  • Young Scientist Award (1st prize) of the German Epidemiological Association
    Deutsche Gesellschaft für Epidemiologie (2005)
  • Promotionsstipendium 2002-2005 / PhD scholarship
    Deutsche Forschungsgemeinschaft (2002)

  • Master in Epidemiology at the University of Bremen
  • Bachelor in Public Health at the University of Bremen

The responsibility for the content of this page lies with Ulrike Haug.

Ulrike Haug


+49 (0)421 218-56-862